泛发性脓疱型银屑病治疗目标的全球德尔菲共识
该研究通过纳入患者代表的全球德尔菲专家组,对基于系统文献综述生成的26条GPP治疗目标陈述进行投票,共识定义为≥80%赞同。首轮投票即达成共识,26条中23条赞同率≥90%,明确了总体原则及短期和长期治疗目标。
要点
- GPP需及时、个体化、多学科治疗,并由医患共同制定方案。
- 短期目标包括7天内脓疱清除、预防复发及3天内退热等。
- 有银屑病共病者治疗决策应优先针对GPP。
核心结论
- 全球首个纳入患者视角的GPP德尔菲共识在总体原则及短期、长期治疗目标上达成一致。
研究设计与样本
- 德尔菲小组由30名皮肤科医生和3名患者代表组成,来自24个国家,对26条陈述投票,共识定义为≥80%赞同。
主要发现
- 首轮投票即达成共识,26条中23条赞同率≥90%。
- 患者代表与医生对部分目标重要性看法存在差异,如避免毛发/甲缺失仅24/30名医生赞同。
关键数值与推荐
- 短期目标:7天内脓疱清除并预防复发,瘙痒与皮肤疼痛数字评分量表下降≥4分,治疗开始3天内退热。
- 有银屑病共病者治疗决策应优先针对GPP。
- 长期目标包括预防复发、发作间期症状控制、持续疾病控制、共病管理和生活质量改善。
临床怎么用
- 临床可参照共识设定的短期与长期目标制定GPP治疗方案并评估疗效。
- 治疗计划应由医患共同制定并采用多学科方法。
- 应重视患者对生活质量相关目标的关切。
局限性
- 原文未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease. A previous Delphi panel established areas of consensus on GPP, although patient perspectives were not included and aspects of treatment goals remained unclear. OBJECTIVES: To identify and achieve consensus on refined, specific treatment goals for GPP treatment via a Delphi panel with patient participation. METHODS: Statements were generated based on a systematic literature review and revised by a Steering Committee. Statements were categorized into overarching principles, and short- and long-term treatment goals. A global panel of 30 dermatologists and 3 patient representatives voted in agreement or disagreement with each statement. Consensus was defined as ≥ 80% approval by the panellists. RESULTS: Consensus was reached in the first round of voting and ≥ 90% agreement was reached for 23 of 26 statements. In summary, GPP requires a timely, tailored treatment plan, co-developed by patients and physicians, that involves a multidisciplinary approach and addresses the complexity, heterogeneity and chronicity of the disease. Short-term treatment goals should include pustule clearance within 7 days and prevention of pustule recurrence, reduction of cutaneous symptom burden (-4 or more points on the Itch and Skin Pain Numeric Rating Scale), improvement in systemic symptoms (e.g. resolution of fever within 3 days of treatment initiation and reduced fatigue), prevention of life-threatening complications and progressive improvement of inflammatory biomarkers. In patients with comorbid psoriatic diseases, treatment decisions should prioritize GPP. Long-term treatment goals should include minimizing disease activity through flare prevention and symptom control between flares, sustained disease control, management of comorbidities and improvement in quality of life (QoL). Small differences in perception between patients and physicians regarding the importance of certain treatment goals (e.g. avoiding hair and/or nail loss to improve QoL), reflect the complexity of assessing treatment goals and emphasize the need for a patient-centred approach. CONCLUSIONS: In the first global Delphi panel in GPP to include patient perspectives, consensus between dermatologists and patients was achieved on overarching principles of treatment, and short- and long-term treatment goals for GPP. These findings provide valuable insights for developing guidelines that consider the perspectives of patients and physicians in the treatment of GPP. Generalized pustular psoriasis (‘GPP’ for short) is a rare and life-long inflammatory disease that causes skin redness and blisters. People with GPP often experience a high temperature, tiredness and skin pain. The symptoms can suddenly become worse in episodes called ‘flares’. Until now, doctors have not had standard treatment goals for GPP, or agreed ways to measure if a medicine is working well. To determine what treatment goals are important to people with GPP and their doctors, a panel of 30 expert doctors and 3 patient representatives from 24 countries took part in a survey. The panel voted on 26 statements related to GPP treatment. The statements were prepared by a team of expert doctors. After 1 round of voting, the panel agreed on all the statements. Regarding GPP treatment, at least 32 out of 33 panellists agreed on each statement. The panel agreed that GPP is a complex, life-long disease, and that treatment should be started quickly, be tailored to each patient and involve doctors from other specialties, as well as dermatologists (skin doctors). Doctors and patient representatives gave different levels of importance to some treatment goals. For example, the 3 patient representatives all agreed that avoiding losing their hair/nails was important, but only 24 out of 30 doctors held the same view. This particular type of survey on GPP treatment goals was the first to include patient representatives. Panellists agreed on all short-term, long-term and overall treatment goals for GPP.
引用
- Barker JN, Casanova E, Choon SE, et al. Global Delphi consensus on treatment goals for generalized pustular psoriasis. Br J Dermatol. 2025. PMID: 39844356. doi:10.1093/bjd/ljae491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。